PATENT CLAIM ANALYSIS

Application Number: 15961992
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "456000"]

Abstract:
Disclosed herein are methods of treating cognitive and behavioral impairment in Down syndrome and/or Alzheimer's disease patients, Alzheimer's disease, neurodegenerative disease, cancer, DYRK1A-mediated disorders and methods of modulating and inhibiting DYRK1-A comprising use of catechins.

Claim (Index 3):
The method according to  claim 1 , comprising (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 91.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14237167', '13863781', '14991037', '12310708', '14780214']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7471435483944879
- 35 USC 102 Novelty (BERT): 0.5591681273191047
- Combined Prediction Score: 0.7283460062869497
- Mean Citation Score: 327.350818
- Max Citation Score: 430.77432000000016
- Similarity Product: 324.39659135169984

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test